Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma

Review proposal consultation

Stakeholder matrix (PDF 104 KB)

Review proposal paper (PDF 240 KB)

TA121 Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide: guidance (MS Word format) (MSWord 666 KB)

Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide: review proposal - August 2010 information

Appendix A: provisional matrix of stakeholders (PDF 31 KB)

Appendix B: proposal paper presented to the Institute's Guidance Executive (PDF 62 KB)

NICE issues guidance on the use of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma information

Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide: Review Decision - October 2010 information

Appendix A: Decision paper considered by the Institute's Guidance Executive (PDF 39 KB)

Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide: final appraisal determination information

Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide: final appraisal determination (PDF 147 KB)

Response to consultee, commentator and public comments on the ACD and comments from website consultation (PDF 170 KB)

Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide: appraisal consultation document information

Glioma overview (PDF 75 KB)

2006/060 NICE appraisal on carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma information

2006/060 NICE appraisal on carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma (PDF 42 KB)

Appeal announcement - Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma information

Methods for reanalyses of cost-effectiveness of TMZ based on subgroup (PDF 70 KB)

Final Appraisal Determination: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide information

Final Appraisal Determination: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide (PDF 137 KB)

Response to consultee and commentator comments on the ACD (PDF 348 KB)

Consultee and commentator comments on the ACD

Association of British Neurologists (PDF 35 KB)

Brain and Spine Foundation (PDF 42 KB)

Brain Tumour UK (PDF 39 KB)

Cancer Research UK (PDF 28 KB)

CancerBACUP (PDF 14 KB)

Department of Health (PDF 14 KB)

Institute of Cancer Research (PDF 38 KB)

Link Pharmaceuticals Ltd (PDF 153 KB)

National Hospital for Neurology & Neurosurgery (PDF 17 KB)

NHS Quality Improvement Scotland (PDF 43 KB)

Royal College of Radiologists (RCR), the Joint Collegiate Council on Clinical Oncology (JCCCO) and the Royal College of Physicians (RCP) (Joint Comments) (PDF 69 KB)

Samantha Dickson Research Trust (PDF 201 KB)

Schering-Plough Ltd (PDF 133 KB)

Society of British Neurological Surgeons (PDF 101 KB)

Welsh Assembly Government (PDF 43 KB)

Response to public and web comments on the ACD (PDF 71 KB)

Expert comments on the ACD

Redman (PDF 21 KB)

Mitchell (PDF 28 KB)

Brada (PDF 23 KB)

Additional analyses

Re-analysis/sensitivity analysis with different treatment on disease progression between TMZ with RT and RT only arm (PDF 23 KB)

Re-analysis based on Link comments on ACD Appendix 2 (PDF 28 KB)

Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide (appraisal consultation) information

Overview (PDF 73 KB)

Assessment report: Glioma (newly diagnosed and high grade) - carmustine implants and gemozolomide (PDF 1.8 MB)

Consultee and commentator comments on the assessment report

Association of British Neurologists (PDF 25 KB)

Brain & Central Nervous System Tumours Guideline Development Group (PDF 33 KB)

British National Formulary (PDF 33 KB)

British Oncology Pharmacy Association (PDF 53 KB)

CancerBACUP (PDF 17 KB)

Link Pharmaceuticals Ltd (PDF 555 KB)

NHS Quality Improvement Scotland (PDF 108 KB)

Royal College of Nursing (PDF 16 KB)

Society of British Neurological Surgeons (SBNS) (PDF 37 KB)

Schering-Plough Ltd (PDF 118 KB)

Response to consultee and commentator comments on the commercial-in-confidence stripped assessment report (PDF 119 KB)

Additional analysis submitted by assessment group in response to consultee and commentator comments (PDF 52 KB)

Non-manufacturer submissions

Brain and Spine Foundation (PDF 54 KB)

CancerBACUP (PDF 41 KB)

Royal College of Nursing (PDF 55 KB)

Tenovus Cancer Information Centre (PDF 28 KB)

Manufacturer submissions (executive summary only)

Link Pharmaceuticals Ltd (PDF 33 KB)

Schering-Plough Ltd (PDF 26 KB)

Expert written personal statements

Brada (PDF 29 KB)

Cruickshank (PDF 36 KB)

Rees (PDF 26 KB)

Walker (PDF 30 KB)

Mitchell (PDF 33 KB)

Final scope (PDF 28 KB)

Summary of comments from consultees and commentators on the draft scope (PDF 41 KB)

Response to comments on the provisional matrix of consultees and commentators (PDF 21 KB)

Archive: Provisional matrix of consultees and commentators (PDF 29 KB)